Uncover the next big thing with financially sound penny stocks that balance risk and reward.
To own Adtalem Global Education, you need to believe in its position as a scaled healthcare and professional education provider that can keep growing earnings while returning substantial cash to shareholders. The new US$750 million buyback authorization, on top of the completed US$150 million program, reinforces a story centered on disciplined capital allocation and confidence in the company’s cash generation. In the near term, key catalysts still hinge on enrollment trends across Chamberlain, Walden, and the Medical and Veterinary segment, along with any fresh detail at the February 2026 Investor Day. The sharp step-up in repurchase capacity may support earnings per share and sentiment after a weak 3‑month share price stretch, but it does not remove core risks around regulation, pricing pressure in education, or potential scrutiny of management pay versus performance.
However, there is an important regulatory and execution risk here that investors should not overlook. Adtalem Global Education's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Explore 2 other fair value estimates on Adtalem Global Education - why the stock might be worth just $158.25!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com